Dose-response efficacy and safety of lumateperone in bipolar depression: A preliminary meta-analysis of randomized controlled trials
Preliminary evidence suggests that 42 mg daily of lumateperone may provide clinical benefit in bipolar depression, yet the higher rate of AE-related discontinuation warrants caution in practice. However, current data remain limited, requiring further studies to establish the optimal dosing range balancing efficacy and safety.
Authors
- Kuo‐Chuan Hung (ORCID: https://orcid.org/0000-0002-4507-8085)
- Yu‐Kang Tu (ORCID: https://orcid.org/0000-0002-2461-474X)
- Chih‐Sung Liang (ORCID: https://orcid.org/0000-0003-1138-5586)
- Yang‐Chieh Brian Chen (ORCID: https://orcid.org/0000-0003-0622-9175)
- Chih‐Wei Hsu (ORCID: https://orcid.org/0000-0002-8650-4060)
- Ping-Tao Tseng
Institutions
- Tri-Service General Hospital (TW)
- National Sun Yat-sen University (TW)
- Asia University (TW)
- National Taiwan University (TW)
- Chang Gung University (TW)
- Kaohsiung Chang Gung Memorial Hospital (TW)
- Chi Mei Medical Center (TW)
- National Defense Medical Center (TW)
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- Journal of Psychopharmacology
- Published
- 2025-08-28
- DOI
- https://doi.org/10.1177/02698811251364389
- Citations
- 1
- Primary Topic
- Bipolar Disorder and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.47
Funders
- Chang Gung Medical Foundation
- National Science and Technology Council